Thieler Law Corp advises investors with losses exceeding $100,000 of the June 17, 2019 lead plaintiff deadline in a class action lawsuit filed against Apyx Medical Corporation (NASDAQ: APYX) (“Apyx” or “the Company”). The suit is pending in the U.S. District Court for the Middle District of Florida and investors, who purchased Apyx Medical Corporation securities between August 1, 2018 and April 1, 2019, have until June 17, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Apyx Medical Corporation securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the clinical study on the use of J-Plasma, a plasma-based surgical product for cutting, coagulation, and ablation of soft tissue, for dermal resurfacing had not met its primary efficacy endpoint; the clinical study did not support Apyx’s application for regulatory clearance; Apyx was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and as a result of the foregoing, Defendants’ positive statements about Apyx’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

On February 21, 2019, a report by White Diamond Research claimed that a clinical study on the use of the Company’s J-Plasma for dermal resurfacing may have missed its endpoints.

Following this news, NASDAQ: APYX fell $2.10 per share, or nearly 25%, to close at $6.40 on February 21, 2019.

On April 1, 2019, the Company revealed that it had withdrawn its 510(k) application for the use of J-Plasma for dermal resurfacing, citing concerns raised by the FDA. Apyx revealed that the FDA had questioned the device’s clinical results, which differed greatly from two of the investigational centers used in the study, as well as the potential impact certain protocol deviations. Additionally, Apyx disclosed that the clinical study did not meet its primary efficacy endpoint.

Following this news, NASDAQ: APYX fell $2.49 per share, or over 35%, to close at $4.46 on April 2, 2019.

If you were negatively impacted by your investment in Apyx Medical Corporation securities between August 1, 2018 and April 1, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185